Neurology Specific Literature Search   
 
[home][thesaurus]
    

Differential
(Click to cross reference)
advances in neurology
adverse drug reaction
alemtuzumab
alopecia
aspergillosis
brachial plexus injury
brachial plexus neuropathy
cardiac surgery
cardiac surgery, neurologic complications with
cardiac transplantation
central nervous system, infection of
cerebral hypersensitivity, delayed
cerebral ischemia
cerebrovascular accident
complications
cyclosporine
daclizumab
demyelinating disease
dermatomyositis
drug induced neurologic disorders
efficacy
encephalopathy
encephalopathy, anoxic
eosinophilia
fungal infection, CNS
gadolinium
Guillain Barre syndrome
hepatic failure
herpes zoster
hypersensitivity reaction
iatrogenic neurologic disorders
immunomodulation
immunosuppression
immunosuppressive agents
immunotherapy
infliximab
interferon
interferon beta 1-a
interleukin 2
limbic encephalitis
lymphadenopathy
lymphoma, primary of CNS
meningitis
meningitis, bacterial
meningitis, listeria monocytogenes
meningitis, pneumococcal
meningitis, TB
monoclonal antibodies
mortality
MRI
MRI, abnormal
MRI, contrast enhanced
multiple sclerosis
multiple sclerosis, relapsing
multiple sclerosis, treatment of
natalizumab
neuromyelitis optica (Devic's disease)
neuropathy
neuropathy, iatrogenic
neuropathy, immune
neuropathy, medication induced
neuropathy, motor, multifocal
neuropathy, peripheral, treatment
opportunistic infection, CNS
polymyositis
polyneuropathy, chronic inflammatory demyelinating
posterior leukoencephalopathy syndrome
postoperative neurologic complications
prognosis
progressive multifocal leucoencephalopathy
rash
review article
risk factors
rituximab
safety
seizure
skin, lesions in neurologic disorders
systemic illness
thrombocytopenia
toxoplasmosis, CNS
transient ischemic attack
treatment of neurologic disorder
tuberculosis
tumor necrosis factor inhibitor
ventricular assist device
Showing articles 0 to 9 of 9

Drug Reaction with Eosinophilia and Systemic Symptoms after Daclizamub Therapy
Neurol 91:e359-e363, Rauer,S.,et al, 2018

Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
NEJM 373:1418-1428, Kappos, L.,et al, 2015

Daclizumab-Induced Adverse Events in Multiple Organ Systems in Multiple Sclerosis
Neurol 82:984-988, Oh, J.,et al, 2014

Daclizumab High-Yield Process in Relapsing-Remitting Multiple Sclerosis (SELECT): A Randomised, Double-Blind, Placebo-Controlled Trial
Lancet 381:190-194, Gold, R.,et al, 2013

Daclizumab High-Yield Process in Relapsing-Remitting Multiple Sclerosis (SELECT): A Randomised, Double-Blind, Placebo-Controlled Trial
Lancet 381:2167-2175, Gold, R.,et al, 2013

Infectious and Non-Infectious Neurologic Complications in Heart Transplant Recipients
Medicine 89:166-175, Mu�oz,P., et al, 2010

Monoclonal Antibody Therapies and Neurologic Disorders
Arch Neurol 65:1162-1165, Novack,J.C.,et al., 2008

Daclizumab Phase II Trial in Relapsing and Remitting Multiple Sclerosis
Neurol 69:785-789, Rose,J.W.,et al, 2007

Emerging Monoclonal Antibody Therapies for Multiple Sclerosis
Neurologist 12:171-178, Cree,B., 2006



Showing articles 0 to 9 of 9